Pharmaceutical Resource Technology, Inc.

S-1/A amended

S-1/A amended

Price $0.50 · 100,000,000 shares · Gross proceeds $50,000,000

Pharmaceutical Resource Technology, Inc. is offering 100,000,000 shares of common stock at $0.50 per share, with a resale component allowing selling stockholders to offer up to 170,175,496 shares. The company operates in Singapore, manufacturing dietary supplements, skincare products, and honey straws, while also engaging in building and construction services. The offering is self-underwritten with no commissions, and proceeds will fund manufacturing expansion, capital expenditures, and general corporate purposes. The company lacks a public market for its stock and faces significant risks including speculative investment, potential illiquidity, and conflicts of interest due to management's control.

S-1/A amended

Price $0.50 · 100,000,000 shares · Gross proceeds $49,908,000

Pharmaceutical Resource Technology, Inc. is conducting an S-1/A filing for an offering of 100,000,000 shares of common stock at $0.50 per share. The offering is self-underwritten with no commissions, led by the CEO, and will last up to 365 days (extendable by the board). The company operates in dietary supplements, skincare, honey straws, and construction in Singapore. Proceeds will fund working capital, and the company plans to seek OTCQB listing, though no assurance of market development is provided. The offering includes risks related to lack of liquidity, penny stock classification, and speculative nature.

S-1 filed

Pharmaceutical Resource Technology, Inc. has filed a new S-1 registration statement for an IPO, following the withdrawal of a previous S-1 filing in 2022. The company, based in Singapore and incorporated in Wyoming, operates in the pharmaceutical technology sector. The current filing includes standard IPO disclosures, with no assurance provided regarding the market value or saleability of the offered shares.

RW withdrawn

Jaison Phyotchem, Inc. has withdrawn its previously filed S-1 registration statement for an upcoming IPO, citing the need for additional time and resources to prepare a new filing. The company emphasizes that no securities have been sold under the withdrawn registration, and it seeks to have fees paid to the SEC credited for future use. The withdrawal highlights ongoing uncertainties in the company's capital-raising strategy.

S-1 filed

Price $0.50 · 56,623,000 shares · Gross proceeds $25,000,000

Jaison Phytochem, Inc. is a pharmaceutical technology company incorporated in Wyoming in 2019, focusing on manufacturing and selling honey straws (plastic tubes filled with honey). The company has entered into licensing agreements with Superbee Network Singapore Pte Ltd for industrial design and patent rights related to honey packaging machinery. The S-1 filing discloses a public offering of 56,623,000 common shares at $0.50 per share, with proceeds intended for operational expenses. The company has no prior public market, and shares are proposed to be quoted on OTC Pink. Key risks include unproven business model, reliance on licensing agreements, and uncertainty in sales projections.